2026 Q1 -tulosraportti
91 päivää sitten
‧28 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenSweden's best case right now considering R/R and potential. Alone on the market, full cash before launch, approved in EU, patent until 2045, possible USA approval soon and voucher worth 1 billion🤑 Ö Several factors speak for an FDA approval of Egetis Therapeutics' drug Emcitate® (tiratricol) for the treatment of MCT8 deficiency. The most crucial factor is that the drug has been granted Priority Review with a PDUFA target date (decision date) set for September 28, 2026. Here are the main reasons why the approval assessment looks strong:Existing approval in EU: Emcitate is already approved and has been launched in Europe, which means that extensive clinical safety and efficacy data has already been validated by European drug authorities. [No planned expert meetings: Upon acceptance of the application, FDA announced that the agency currently does not plan to hold any advisory committee meeting (Advisory Committee). This is often interpreted positively, as it indicates that FDA sees no significant controversies or question marks regarding safety and efficacy. Regulatory status: The drug has previously been granted Breakthrough Therapy Designation and Fast Track Designation, which underscores how urgent it is for a patient group that currently lacks approved treatment options in the USA. Extensive data: The American application (NDA) is based on solid documentation from several studies (including Triac Trial I, Triac Trial II and ReTRIACt) as well as data from an American Expanded Access Program (EAP).Conditionally approved drug name: In April 2026, FDA announced that the proposed drug name Emcitate is conditionally acceptable, which is an administrative milestone reached in the final phase of an approval process. Also consider that they are alone on the market, receive a voucher worth 1 billion, and have strong owners. I believe in a Hole in one
@hajaa: I know the company, have studied it thoroughly. And yes, it looks really attractive. The market has now for a long time 'kept the company at arm's length' awaiting what happens next - and the market is always right. Ladies & Gentlemen☝️☝️ Bet’s please☝️☝️ Closing prices above 6.7ish, alternatively around price 6 - 5.8ish are the primary entries in the ongoing price-action - until they occur, one should just sit on one's hands.
·20.7.If anyone had forgotten it, here is the story of the erroneous target price of 1.6, which is still displayed on Nordnet's page: "benielsen Feb 16 · Edited The low share price is probably due to continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the target price to 1.60. A couple of days later, a target price came from Redeye, which was apparently around 13. Pareto's erroneous analytical basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to disseminate as the "lowest target price" instead of removing it when it was demonstrably based on an error - or asking Pareto to retract their erroneous analysis. Moreover, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another analysis house directly attack Pareto and their analytical basis, as we fortunately saw some do in November. It was highly necessary and commendably fast - and completely unprecedented. If you have forgotten the case, look at the posts below at the end of November. Here is an excerpt from Stifel's correction, which shows Pareto's misconception - but see more below in November. Pareto on Wednesday lowered its recommendation for the share to sell from hold with a target price reduction to 1:60 kronor from previously 6 kronor. In (den fejlagtige) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
91 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenSweden's best case right now considering R/R and potential. Alone on the market, full cash before launch, approved in EU, patent until 2045, possible USA approval soon and voucher worth 1 billion🤑 Ö Several factors speak for an FDA approval of Egetis Therapeutics' drug Emcitate® (tiratricol) for the treatment of MCT8 deficiency. The most crucial factor is that the drug has been granted Priority Review with a PDUFA target date (decision date) set for September 28, 2026. Here are the main reasons why the approval assessment looks strong:Existing approval in EU: Emcitate is already approved and has been launched in Europe, which means that extensive clinical safety and efficacy data has already been validated by European drug authorities. [No planned expert meetings: Upon acceptance of the application, FDA announced that the agency currently does not plan to hold any advisory committee meeting (Advisory Committee). This is often interpreted positively, as it indicates that FDA sees no significant controversies or question marks regarding safety and efficacy. Regulatory status: The drug has previously been granted Breakthrough Therapy Designation and Fast Track Designation, which underscores how urgent it is for a patient group that currently lacks approved treatment options in the USA. Extensive data: The American application (NDA) is based on solid documentation from several studies (including Triac Trial I, Triac Trial II and ReTRIACt) as well as data from an American Expanded Access Program (EAP).Conditionally approved drug name: In April 2026, FDA announced that the proposed drug name Emcitate is conditionally acceptable, which is an administrative milestone reached in the final phase of an approval process. Also consider that they are alone on the market, receive a voucher worth 1 billion, and have strong owners. I believe in a Hole in one@hajaa: I know the company, have studied it thoroughly. And yes, it looks really attractive. The market has now for a long time 'kept the company at arm's length' awaiting what happens next - and the market is always right. Ladies & Gentlemen☝️☝️ Bet’s please☝️☝️ Closing prices above 6.7ish, alternatively around price 6 - 5.8ish are the primary entries in the ongoing price-action - until they occur, one should just sit on one's hands.
- ·20.7.If anyone had forgotten it, here is the story of the erroneous target price of 1.6, which is still displayed on Nordnet's page: "benielsen Feb 16 · Edited The low share price is probably due to continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the target price to 1.60. A couple of days later, a target price came from Redeye, which was apparently around 13. Pareto's erroneous analytical basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to disseminate as the "lowest target price" instead of removing it when it was demonstrably based on an error - or asking Pareto to retract their erroneous analysis. Moreover, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another analysis house directly attack Pareto and their analytical basis, as we fortunately saw some do in November. It was highly necessary and commendably fast - and completely unprecedented. If you have forgotten the case, look at the posts below at the end of November. Here is an excerpt from Stifel's correction, which shows Pareto's misconception - but see more below in November. Pareto on Wednesday lowered its recommendation for the share to sell from hold with a target price reduction to 1:60 kronor from previously 6 kronor. In (den fejlagtige) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
2026 Q1 -tulosraportti
91 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenSweden's best case right now considering R/R and potential. Alone on the market, full cash before launch, approved in EU, patent until 2045, possible USA approval soon and voucher worth 1 billion🤑 Ö Several factors speak for an FDA approval of Egetis Therapeutics' drug Emcitate® (tiratricol) for the treatment of MCT8 deficiency. The most crucial factor is that the drug has been granted Priority Review with a PDUFA target date (decision date) set for September 28, 2026. Here are the main reasons why the approval assessment looks strong:Existing approval in EU: Emcitate is already approved and has been launched in Europe, which means that extensive clinical safety and efficacy data has already been validated by European drug authorities. [No planned expert meetings: Upon acceptance of the application, FDA announced that the agency currently does not plan to hold any advisory committee meeting (Advisory Committee). This is often interpreted positively, as it indicates that FDA sees no significant controversies or question marks regarding safety and efficacy. Regulatory status: The drug has previously been granted Breakthrough Therapy Designation and Fast Track Designation, which underscores how urgent it is for a patient group that currently lacks approved treatment options in the USA. Extensive data: The American application (NDA) is based on solid documentation from several studies (including Triac Trial I, Triac Trial II and ReTRIACt) as well as data from an American Expanded Access Program (EAP).Conditionally approved drug name: In April 2026, FDA announced that the proposed drug name Emcitate is conditionally acceptable, which is an administrative milestone reached in the final phase of an approval process. Also consider that they are alone on the market, receive a voucher worth 1 billion, and have strong owners. I believe in a Hole in one@hajaa: I know the company, have studied it thoroughly. And yes, it looks really attractive. The market has now for a long time 'kept the company at arm's length' awaiting what happens next - and the market is always right. Ladies & Gentlemen☝️☝️ Bet’s please☝️☝️ Closing prices above 6.7ish, alternatively around price 6 - 5.8ish are the primary entries in the ongoing price-action - until they occur, one should just sit on one's hands.
- ·20.7.If anyone had forgotten it, here is the story of the erroneous target price of 1.6, which is still displayed on Nordnet's page: "benielsen Feb 16 · Edited The low share price is probably due to continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the target price to 1.60. A couple of days later, a target price came from Redeye, which was apparently around 13. Pareto's erroneous analytical basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to disseminate as the "lowest target price" instead of removing it when it was demonstrably based on an error - or asking Pareto to retract their erroneous analysis. Moreover, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another analysis house directly attack Pareto and their analytical basis, as we fortunately saw some do in November. It was highly necessary and commendably fast - and completely unprecedented. If you have forgotten the case, look at the posts below at the end of November. Here is an excerpt from Stifel's correction, which shows Pareto's misconception - but see more below in November. Pareto on Wednesday lowered its recommendation for the share to sell from hold with a target price reduction to 1:60 kronor from previously 6 kronor. In (den fejlagtige) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt